Table 4.
Genotype 2-4 infection - treatment-naïve (with compensated cirrhosis) and non-cirrhotic
| No. | First line therapy | Alternative regimen |
| Genotype 2 infection - treatment-naïve and non-cirrhotic | ||
| 1 | Glecaprevir/Pibrentasvir (Mavyret) - 8 wk | Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk |
| 2 | Sofosbuvir/Velpatasvir (Epclusa) - 12 wk | |
| Genotype 2 infection - treatment-naïve with compensated cirrhosis | ||
| 1 | Glecaprevir/Pibrentasvir (Mavyret) - 12 wk | Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 16 to 24 wk |
| 2 | Sofosbuvir/Velpatasvir (Epclusa) - 12 wk | |
| Genotype 3 infection - treatment-naïve and non- cirrhotic | ||
| 1 | Glecaprevir/Pibrentasvir (Mavyret) - 8 wk | Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk |
| 2 | Sofosbuvir/Velpatasvir (Epclusa - 12 wk | |
| Genotype 3 infection - treatment-naïve with compensated cirrhosis | ||
| 1 | Glecaprevir/Pibrentasvir (Mavyret) - 12 wk | Vosevi - Sofosbuvir 400 mg/ Velpatasvir 100 mg/ Voxilaprevir 100 mg when Y93 is present - 12 wk |
| 2 | Sofosbuvir/Velpatasvir (Epclusa) - 12 wk | Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with or without weight-based ribavirin - 24 wk |
| Genotype 4 infection - treatment-naïve and non-cirrhotic | ||
| 1 | Glecaprevir/Pibrentasvir (Mavyret) - 8 wk | Ombitasvir 25 mg/Paritaprevir 150 mg/ Ritonavir 100 mg (Technivie) with weight-based ribavirin - 12 wk |
| 2 | Sofosbuvir/Velpatasvir (Epclusa) - 12 wk | |
| 3 | Elbasvir/Grazoprevir (Zepatier) - 12 wk | |
| 4 | Ledipasvir/Sofosbuvir (Harvoni) - 12 wk | |
| Genotype 4 infection - treatment-naïve with compensated cirrhosis | ||
| 1 | Sofosbuvir/Velpatasvir (Epclusa) - 12 wk | Ombitasvir 25 mg/Paritaprevir 150 mg/ Ritonavir 100 mg (Technivie) with weight-based ribavirin - 12 wk |
| 2 | Glecaprevir/Pibrentasvir (Mavyret) - 12 wk | |
| 3 | Elbasvir/Grazoprevir (Zepatier) - 12 wk | |
| 4 | Ledipasvir/Sofosbuvir (Harvoni) - 12 wk | |